Aktis Oncology (NASDAQ:AKTS) Director Purchases $15,030,000.00 in Stock

Aktis Oncology (NASDAQ:AKTS) Director Helen Susan Kim bought 835,000 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the transaction, the director owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Aktis Oncology Price Performance

Aktis Oncology stock opened at $20.81 on Thursday. Aktis Oncology has a 52 week low of $19.02 and a 52 week high of $29.16.

Trending Headlines about Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Large insider and affiliated investor purchases signal strong insider confidence: Ecor1 Capital bought 2,222,222 shares and directors/affiliates (Helen Susan Kim, Vida Ventures II, Bioventures / Ansbert Gadicke) also made multi‑hundred‑thousand share purchases at the IPO price of $18, materially increasing ownership stakes. These filings show management and key backers are doubling down after the offering. Read More. Read More.
• Positive Sentiment: Upsized IPO delivered substantial cash and strategic validation: Aktis closed an upsized IPO with full exercise of the underwriters’ option, raising roughly $365M (press release) and attracting a large anchor investment from Eli Lilly — providing runway to advance clinical radiopharmaceutical programs. Read More.
• Neutral Sentiment: Market context and sentiment are mixed — the IPO is seen as an early test of biotech market appetite for 2026, with social media and analyst chatter highlighting both optimism for the radiopharmaceutical thesis and debates about near‑term catalysts and valuation. Read More.
• Negative Sentiment: Company fundamentals and short‑term downside risks: Aktis is clinical‑stage and pre‑revenue with thin liquidity ratios (reported quick ratio ~0.28, current ratio ~0.32) and leverage (debt/equity ~1.0). Those metrics increase sensitivity to execution risks and any delays in clinical progress or commercialization. Read More.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.